Nanobiotix S.A.
NNBXF
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.3B
Close$
Share Statistics
| Market cap | $1.30 Billion |
|---|---|
| Enterprise Value | $1.33 Billion |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | 314.58% |
|---|---|
| Return on Assets | -81.83% |
| Return on Invested Capital | -165.35% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 107.32 |
| Enterprise Value to EBIT | -19.05 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | -4.28 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Nanobiotix
89 employees
CEO: Laurent Levy Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of cry...